<DOC>
	<DOCNO>NCT00003484</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell deliver tumor-killing substance , radioactive iodine , without harm normal cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody radiation therapy treat patient newly diagnose primary brain tumor surgically resect .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy Treating Patients With Primary Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity iodine I 131 monoclonal antibody 81C6 deliver via intracranial resection cavity patient newly diagnose primary malignant brain tumor surgery radiotherapy . - Determine objective therapeutic response patient treatment . OUTLINE : This dose escalation study iodine I 131 antitenascin monoclonal antibody 81C6 ( I 131 MAb 81C6 ) . Within 2-4 week completion external beam radiotherapy , patient undergo surgical resection tumor brain metastasis , time indwell intracranial resection cavity catheter place . A single dose I 131 MAb 81C6 deliver via intralesional catheter . Cohorts 3-6 patient receive escalate dos I 131 MAb 81C6 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . After MTD establish , patient phase II portion study receive therapy phase I . Beginning 4 week monoclonal antibody treatment , patient begin chemotherapy . Patients receive carmustine IV 1 hour day 1 irinotecan IV 90 minute weekly 4 week . Treatment repeat every 6 week least 4 course absence disease progression . Patients follow initially 4 week , every 6 week 1 year . PROJECTED ACCRUAL : A total 41 patient accrue study .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose supratentorial primary malignant brain tumor No infratentorial tumor , infiltrate tumor , tumor subependymal spread , multifocal tumor Candidate surgical resection Prior external beam radiotherapy site measurable disease resection site nervous system require Presence tenascin tumor demonstrate immunohistology either polyclonal rabbit antitenascin antibody monoclonal antibody 81C6 PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL Alkaline phosphatase less 1.5 time normal Lactic dehydrogenase less 1.5 time normal SGOT le 1.5 time normal Renal : Creatinine le 1.2 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No iodine allergy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Concurrent corticosteroid allow , must stable dose least 10 day Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult craniopharyngioma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult meningioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult pineal parenchymal tumor</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>